Dualitas

Executive Summary

Dualitas is a preclinical-stage biotechnology company developing bispecific antibody therapies for oncology and autoimmune diseases. Founded in 2019 and headquartered in Boston, the company leverages a proprietary platform to engineer dual-targeting antibodies that simultaneously engage immune cells and tumor cells or disease-driving pathways, aiming to improve therapeutic efficacy and reduce off-target toxicity. The bispecific antibody modality has gained significant traction in recent years, with multiple approved products validating the approach. Dualitas has raised $65 million to advance its pipeline, positioning it for key preclinical milestones. However, as a private company with no disclosed clinical candidates, its technology remains unvalidated in humans, and the competitive landscape for bispecific antibodies is intense, with numerous players targeting similar mechanisms. The company's ability to differentiate its candidates and achieve preclinical proof-of-concept will be critical in attracting further investment and partnerships.

Upcoming Catalysts (preview)

• Q2 2026IND-enabling studies completion75% success
• Q3 2026Lead candidate selection for preclinical pipeline60% success
• Q4 2026Series B or strategic partnership announcement50% success